Research analysts at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.
Get Our Latest Stock Analysis on TRACON Pharmaceuticals
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million during the quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Recommended Stories
- Five stocks we like better than TRACON Pharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- How to Evaluate a Stock Before BuyingÂ
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Airline Stocks – Top Airline Stocks to Buy Now
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.